Effects of Low-Sodium Salt on Death, HF Hospitalization/ Emergency Department Visits and Quality of Life in HF Patients

Heart Health Research Center1,301 enrolled

Overview

This study aims to investigate whether using a low-sodium substitute salt can help improve outcomes for patients with heart failure. Specifically, it will examine if the low-sodium substitute salt can reduce death rates, hospital readmissions, and emergency visits, as well as improve the quality of life for these patients.

The study will involve multiple centers and use a randomized, double-blind, controlled design, where participants will be randomly assigned to either the intervention group (who will use the low-sodium substitute salt ) or the control group (who will use regular salt). Participants will be followed up for at least a year, assessing outcomes including all cause mortality, heart failure hospitalizations, emergency visits, and changes in quality of life as measured by a questionnaire. Eligible participants will be between 18 and 75 years old, have been hospitalized for heart failure in the past year, and have stable heart failure. The study will exclude individuals with severe heart failure, uncontrolled health conditions, or other factors that may interfere with participation. The main goals are to determine if reducing sodium intake through the low-sodium substitute salt leads to better health outcomes in heart failure patients over a year. Participants will be followed up at 3, 6, 9, and 12 months. This research will help provide evidence for whether a simple dietary change, like using a low-sodium substitute salt , can make a meaningful difference in managing heart failure

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

1,301

Conditions

Heart Failure Dietary Sodium Intake

Interventions

low-sodium substitute saltOTHER

This study specifically customized sodium reducing substitute salts with a sodium chloride content not exceeding 62% and without the addition of potassium chloride.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Aged between 18 and 75 years; 2. Hospitalized due to heart failure in the past year; 3. NYHA functional class II-III; 4. Echocardiographic evidence of LVEF \< 40% within the past 6 months; 5. Receiving guideline-directed medical therapy for heart failure; 6. Stable heart failure status, defined as heart failure stability for more than 4 weeks, with no increase in diuretic dose within the past 4 weeks; 7. Having a primary caregiver and frequently dining together at home; 8. Consuming commercially processed food no more than once a week; 9. Providing written informed consent. Exclusion Criteria: 1. End-stage heart failure; 2. Hospitalization due to cardiovascular causes within the past month; 3. Uncorrected hyponatremia (Na \< 130 mmol/L); 4. Dialysis-dependent patients, or eGFR \< 20 mL/min/1.73m²; 5. Uncontrolled hyperglycemia, with fasting blood glucose \> 16 mmol/L; 6. Malignant cancer patients with a life expectancy of less than 1 year; 7. Conditions that, in the investigator's opinion, may interfere with adherence to the protocol, such as habitual reliance on takeout meals or dining at company cafeterias; 8. Planned hospitalization during the study period; 9. Unexplained weight loss greater than 5 kg in the past year; 10. The subject or family members have concerns about using the salt substitute in this study, or are planning for pregnancy, pregnant, or breastfeeding; 11. Another family member is already participating in this study; 12. The subject or family members are participating in other interventional clinical trials.

Locations (1)

Anzhen Hospital, Capital Medical University

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Percentage of pairwise comparisons with wins of a composite endpoint including 1-year death, the number of HF hospitalizations/emergency visits, time to the first HF hospitalization/emergency visit, and the change in quality of life at 12 months

Clinical benefit, a composite of all cause death, the number of HFHs/emergency visits, time to the first HFH/emergency visit, and the change in quality of life (Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) )at 1 year. All patients randomized to low-sodium group are compared to those randomized to control group within strata. For any two patients, a patient will win, i.e. achieve a better clinical outcome, as determined by assessing the following criteria sequentially, stopping when an advantage for either patient is shown: 1. Death: death is worse than no death; earlier death is worse; tied if not possible to determine. 2. Number of HF hospitalizations/emergency visits,: more HFHs/emergency visits is worse; tied, if same number. 3. Time to first HFH/emergency visit: earlier HFH/emergency visit is worse; tied, if not possible to determine. 4. KCCQ-12 at 1 year: Higher KCCQ-12 is better. The KCCQ-12 ranges from 0 to 100, where a higher score reflects a better outcome.